Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation

Journal of Interventional Cardiac Electrophysiology

Volumn 40, Issue 1, 2014, Pages 33-38

  Stepanyan, Gevorg ^a   Badhwar, Nitish ^a   Lee, Randall J ^a   Marcus, Gregory M ^a   Lee, Byron K ^a   Tseng, Zian H ^a   Vedantham, Vasanth ^a   Olgin, Jeffrey ^a   Scheinman, Melvin ^a   Gerstenfeld, Edward P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Catheter ablation; Pulmonary vein isolation; Stroke

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; HEPARIN; RIVAROXABAN; WARFARIN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANTICOAGULATION; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BRAIN EMBOLISM; CATHETER ABLATION; DRUG SAFETY; FALSE ANEURYSM; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PRIORITY JOURNAL; THROMBOEMBOLISM; AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; PULMONARY VEIN; RETROSPECTIVE STUDY;

AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PULMONARY VEINS; RETROSPECTIVE STUDIES; THIOPHENES; THROMBOEMBOLISM; WARFARIN;

EID: 84903376055     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-014-9888-9     Document Type: Article

References (18)

1. Kannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. (1998). Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. The American Journal of Cardiology, 82, 2N-9N. (Pubitemid 28507114)
2. Wann, L., Curtis, A., January, C. T., Ellenbogen, K., Lowe, J., Estes, M., et al. (2011). 2011 ACCF/AHA/HRS Focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 57(2), 223-242.
3. Coppens, M., Eikelboom, J., Hart, R., Yusuf, S., Lip, G., Dorian, P., et al. (2013). The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. European Heart Journal, 34(3), 170-176.
4. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigitran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361, 1139-1151.
5. Patel, M. R., Mahaffey, K. W., Garg, J., the ROCKET AF Steering Committee, for the ROCKET AF Investigators, et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 385(10), 883-891.
6. Calkins, H., Kuck, K., Cappato, R., Brugada, J., Camm, J., Chen, S., et al. (2012). 2012 HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research. J Interv Card Electrophysiol 33, 171-257.
7. Hussein, A. A., Martin, D. O., Saliba, W., Patel, D., Karim, S., Batal, O., et al. (2009 Oct). Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 6(10), 1425-1429.
8. Fuster, V., Ryden, L., Cannom, D., Crijns, H., Curtis, A., Ellenbogen, K., et al. (2011). 2011 ACCF/AHA/HRS Focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation, 123, e269-e36.
9. Lakkireddy, D., Reddy, Y. M., Di Biase, L., et al. (2012). Feasibility and safety of dabigatran versus warfarin for peri-procedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal of the American College of Cardiology, 59, 956-967.
10. Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., & Patrawala, R. A. (2012). The use of dabigatran immediately after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 23, 264-268.
11. Snipelisky, D., Kauffman, C., Prussak, K., Johns, G., Venkatachalam, K., & Kusumoto, F. (2012 Oct). A comparison of bleeding complications post-ablation between warfarin and dabigatran. Journal of Interventional Cardiac Electrophysiology, 35(1), 29-33.
12. Kim, J. S., She, F., Jongnarangsin, K., Chugh, A., Latchamsetty, R., Ghanbari, H., et al. (2013). Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm, 10(4), 483-489.
13. Kaiser, D. W., Streur, M. M., Nagarakanti, R., Whalen, S. P., & Ellis, C. R. (2013). Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. Journal of Interventional Cardiac Electrophysiology, 37(3), 241-247.
14. Nin, T., Sairaku, A., Yoshida, Y., Kamiya, H., et al. (2013). A randomized controlled trail of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. PACE, 36, 172-179.
15. Maddox, W., Kay, G. N., Yamada, T., et al. (2013). Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 24, 861-865.
16. Bassiouny, M., Saliba, W., Rickard, J., et al. (2013). Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circulation. Arrhythmia and Electrophysiology, 6, 460-466.
17. Eitel, C., Koch, J., Sommer, P., John, S., Kircher, S., Bollmann, A., Arya, A., Piorkowski, C., Hindricks, G., (2013). Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace May 22. (Epub ahead of print).
18. Lakkireddy, D., Reddy, M., Swarup, V., Baqdunes, M., Mansour, M., Chaloub, F., Ruskin, J., DiBiase, L., Vallakatti, A., Janga, P., Umbarger, L., Sanchez, J., Burkhardt, D., Horton, R., Reddy, V. A, D'Avila, Atkins, D., Bommana, S., Natale, A., (2013) Uninterrupted rivaroxaban vs. warfarin for periprocedural anticoagulation during atrial fibrillation ablation: a multicenter experience. Heart Rhythm. May;10(5)S240. (Abstract).